SPOTLIGHT -
EP. 1: Introduction and Frontline Treatment of RCC
EP. 2: High-Risk Renal Cell Carcinoma Treatment
EP. 3: Prognostic Factors and Treatment Selection in RCC
EP. 4: Risk Stratification in Renal Cell Carcinoma
EP. 5: Role of Cytoreductive Nephrectomy in mRCC
EP. 6: Alternative Dosing Schedules for Targeted Agents in RCC
EP. 7: Treatment-Related Adverse Events in RCC
EP. 8: Treatment Considerations in Renal Cell Carcinoma
EP. 9: First-line Therapy for Renal Cell Carcinoma
EP. 10: Second-Line Treatment Selection in RCC
EP. 11: Immunotherapy in Renal Cell Carcinoma
EP. 12: Nivolumab in Renal Cell Carcinoma
EP. 13: PD-1 Inhibition in Renal Cell Carcinoma
EP. 14: Role of TKIs in Oligometastatic RCC
EP. 15: Palliative Care for Patients With RCC
EP. 16: Changing Treatment Landscape for RCC
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
